<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Morning Brief - February 3, 2026</title>
<style>
:root{--bg:#0f172a;--card:#1e293b;--text:#f8fafc;--muted:#94a3b8;--accent:#e11d48;--green:#22c55e;--blue:#3b82f6;--purple:#a855f7}
*{margin:0;padding:0;box-sizing:border-box}
body{font-family:system-ui,sans-serif;background:var(--bg);color:var(--text);line-height:1.7;padding:2rem}
.container{max-width:900px;margin:0 auto}
.back{color:var(--accent);text-decoration:none;display:inline-flex;align-items:center;gap:.5rem;margin-bottom:2rem}
.back:hover{text-decoration:underline}
h1{font-size:2rem;margin-bottom:.5rem}
.meta{color:var(--muted);margin-bottom:2rem;padding-bottom:1rem;border-bottom:1px solid #334155}
.study{background:var(--card);border-radius:1rem;padding:1.5rem;margin-bottom:1.5rem;border:1px solid #334155}
.study-header{display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:1rem;flex-wrap:wrap;gap:1rem}
.study-badge{font-size:.7rem;padding:.35rem .75rem;border-radius:.25rem;text-transform:uppercase;letter-spacing:.05em}
.badge-structural{background:rgba(225,29,72,.2);color:var(--accent)}
.badge-interventional{background:rgba(59,130,246,.2);color:var(--blue)}
.badge-editorial{background:rgba(34,197,94,.2);color:var(--green)}
.study h2{font-size:1.25rem;color:var(--text);margin-bottom:.5rem}
.study-meta{font-size:.85rem;color:var(--muted);margin-bottom:1rem}
.study-meta a{color:var(--accent);text-decoration:none}
.study-meta a:hover{text-decoration:underline}
.summary-box{background:rgba(225,29,72,.1);border-left:3px solid var(--accent);padding:1rem;margin:1rem 0;border-radius:0 .5rem .5rem 0}
.summary-box h4{font-size:.85rem;text-transform:uppercase;color:var(--accent);margin-bottom:.5rem}
.key-numbers{display:grid;grid-template-columns:repeat(auto-fit,minmax(120px,1fr));gap:1rem;margin:1rem 0}
.key-number{background:#0f172a;padding:1rem;border-radius:.5rem;text-align:center}
.key-number .value{font-size:1.5rem;font-weight:700;color:var(--accent)}
.key-number .label{font-size:.75rem;color:var(--muted)}
.clinical-pearl{background:linear-gradient(135deg,rgba(34,197,94,.1),rgba(34,197,94,.05));border:1px solid rgba(34,197,94,.3);padding:1rem;border-radius:.5rem;margin:1rem 0}
.clinical-pearl::before{content:"üíé Clinical Pearl: ";font-weight:600;color:var(--green)}
.social-buzz{background:rgba(59,130,246,.1);padding:1rem;border-radius:.5rem;margin:1rem 0}
.social-buzz h4{font-size:.85rem;color:var(--blue);margin-bottom:.5rem;display:flex;align-items:center;gap:.5rem}
.social-buzz p{font-size:.9rem;color:var(--muted)}
ul{margin:1rem 0 1rem 1.5rem}
li{margin:.5rem 0}
a.study-link{display:inline-flex;align-items:center;gap:.5rem;color:var(--accent);text-decoration:none;font-size:.9rem;margin-top:.5rem}
a.study-link:hover{text-decoration:underline}
.quick-hits{background:var(--card);border-radius:1rem;padding:1.5rem;margin:2rem 0;border:1px solid #334155}
.quick-hits h2{font-size:1.25rem;margin-bottom:1rem;display:flex;align-items:center;gap:.5rem}
.quick-hit{padding:1rem 0;border-bottom:1px solid #334155}
.quick-hit:last-child{border-bottom:none;padding-bottom:0}
.quick-hit h4{font-size:1rem;margin-bottom:.5rem}
.quick-hit p{color:var(--muted);font-size:.9rem}
.download-section{display:flex;gap:1rem;flex-wrap:wrap;margin-top:2rem;padding-top:2rem;border-top:1px solid #334155}
.download{padding:1rem 2rem;background:var(--accent);color:white;text-decoration:none;border-radius:.5rem;display:inline-flex;align-items:center;gap:.5rem}
.download:hover{opacity:.9}
.download.secondary{background:var(--card);border:1px solid #334155}
.footer{margin-top:3rem;color:var(--muted);font-size:.875rem;text-align:center}
</style>
</head>
<body>
<script src="../auth.js"></script>
<div class="container">
<a href="../index.html#briefs" class="back">‚Üê Back to Dashboard</a>

<h1>‚òÄÔ∏è Morning Brief</h1>
<p class="meta">Monday, February 3, 2026 | Prepared for Dr. Peter Bleszynski, MD, FACC, FSCAI</p>

<!-- STUDY 1: Complex PCI in Severe AS -->
<div class="study">
  <div class="study-header">
    <span class="study-badge badge-interventional">Registry Data</span>
  </div>
  <h2>ASCoP Registry: Complex High-Risk PCI in Patients with Severe Aortic Stenosis</h2>
  <p class="study-meta">
    <strong>Authors:</strong> Montalto C, Bedogni F, Van Mieghem N, Sondergaard L, Saia F, De Backer O, et al.<br>
    <strong>Journal:</strong> EuroIntervention | April 2025 | <a href="https://pubmed.ncbi.nlm.nih.gov/40259842/" target="_blank">üîó PubMed</a>
  </p>
  
  <div class="summary-box">
    <h4>Executive Summary</h4>
    <p>International registry examining outcomes of complex, high-risk PCI in patients with concomitant severe AS and an indication for TAVR. Addresses the sequencing question: PCI first, TAVR first, or concomitant?</p>
  </div>

  <p><strong>Key Points:</strong></p>
  <ul>
    <li>Examines patients with <strong>dual indication:</strong> TAVR + complex PCI</li>
    <li>Compares different treatment strategies and timing</li>
    <li>Real-world outcomes from high-volume international centers</li>
    <li>Helps define optimal approach for complex CAD + severe AS</li>
    <li>Safety and efficacy data across different strategies</li>
  </ul>

  <div class="clinical-pearl">This is the exact population you see in your practice‚Äîpatients who need both TAVR and complex PCI. The ASCoP registry provides evidence to support Heart Team discussions on sequencing.</div>

  <div class="social-buzz">
    <h4>üì± #CardioTwitter Buzz</h4>
    <p>"PCI first or TAVR first?" remains hotly debated. ASCoP data being cited in ongoing discussions. Consider lesion complexity, symptom driver, and hemodynamic status. #TAVR #ComplexPCI</p>
  </div>

  <a href="https://pubmed.ncbi.nlm.nih.gov/40259842/" target="_blank" class="study-link">üìÑ Read Full Study ‚Üí</a>
</div>

<!-- STUDY 2: Residual SYNTAX Score -->
<div class="study">
  <div class="study-header">
    <span class="study-badge badge-structural">Propensity-Matched Analysis</span>
  </div>
  <h2>Residual SYNTAX Score: TAVR+PCI vs SAVR+CABG Gender-Based Comparison</h2>
  <p class="study-meta">
    <strong>Authors:</strong> Potratz M, Bleiziffer S, Rudolph TK, et al. (German Centers)<br>
    <strong>Journal:</strong> Open Heart | September 2025 | <a href="https://pubmed.ncbi.nlm.nih.gov/41033711/" target="_blank">üîó PubMed (Free PMC)</a>
  </p>
  
  <div class="summary-box">
    <h4>Executive Summary</h4>
    <p>Propensity-matched comparison of residual SYNTAX scores and outcomes in TAVR+PCI vs SAVR+CABG, with gender-based subgroup analysis. Examines completeness of revascularization and its impact on outcomes.</p>
  </div>

  <p><strong>Key Findings:</strong></p>
  <ul>
    <li><strong>Residual SYNTAX score</strong> as a metric for revascularization completeness</li>
    <li>Gender-specific outcomes analysis‚Äîimportant given different CAD patterns</li>
    <li>TAVR+PCI increasingly used as traditional surgical approach</li>
    <li>Addresses whether incomplete revascularization matters differently by approach</li>
  </ul>

  <div class="clinical-pearl">Residual SYNTAX after PCI matters. This study quantifies the impact‚Äîand suggests we shouldn't assume surgical revascularization always achieves complete revascularization either. Gender differences are worth noting.</div>

  <a href="https://pubmed.ncbi.nlm.nih.gov/41033711/" target="_blank" class="study-link">üìÑ Read Full Study ‚Üí</a>
</div>

<!-- STUDY 3: Editorial on TAVI in Small Roots -->
<div class="study">
  <div class="study-header">
    <span class="study-badge badge-editorial">Editorial</span>
  </div>
  <h2>From Gradients to Lifetime Strategy: Rethinking TAVI in Small Aortic Roots</h2>
  <p class="study-meta">
    <strong>Author:</strong> Francesco Maisano<br>
    <strong>Journal:</strong> EuroIntervention | February 3, 2026 | <a href="https://eurointervention.pcronline.com/article/from-gradients-to-lifetime-strategy-rethinking-tavi-choice-in-small-aortic-roots" target="_blank">üîó Full Text (Free)</a>
  </p>
  
  <div class="summary-box">
    <h4>Executive Summary</h4>
    <p>Thought-provoking editorial from Francesco Maisano on the evolution of TAVR in small aortic roots. Discusses moving beyond simple gradient measurements toward lifetime management planning.</p>
  </div>

  <p><strong>Key Themes:</strong></p>
  <ul>
    <li><strong>Lifetime management:</strong> Thinking beyond the index procedure</li>
    <li>Innovation needed to address unmet needs in small roots</li>
    <li>Balance between hemodynamic optimization and future options</li>
    <li>Calls for better patient-specific planning tools</li>
    <li>Sets the stage for emerging technologies like DurAVR</li>
  </ul>

  <div class="clinical-pearl">Maisano's perspective is worth reading. As TAVR extends to younger patients, we need to think beyond the implant‚Äîwhat happens in 10-15 years? Coronary access, redo options, and valve durability all factor in.</div>

  <div class="social-buzz">
    <h4>üì± #CardioTwitter Buzz</h4>
    <p>Editorial generating discussion on "lifetime strategy" concept. Are we adequately planning for redo procedures? Should valve selection factor in 20-year plans? #TAVR #LifetimeManagement</p>
  </div>

  <a href="https://eurointervention.pcronline.com/article/from-gradients-to-lifetime-strategy-rethinking-tavi-choice-in-small-aortic-roots" target="_blank" class="study-link">üìÑ Read Editorial ‚Üí</a>
</div>

<!-- QUICK HITS -->
<div class="quick-hits">
  <h2>‚ö° Quick Hits</h2>
  
  <div class="quick-hit">
    <h4>üî¨ PCI Outcomes Post-TAVR: Multicenter Registry</h4>
    <p><strong>Pivato CA, Stefanini G, et al. | Eur Heart J Open</strong> | <a href="https://pubmed.ncbi.nlm.nih.gov/40980722/" target="_blank">Full Text (Free PMC)</a><br><br>
    Large multicenter registry of consecutive patients undergoing PCI after TAVR. As this population grows, understanding their unique PCI outcomes is critical. Prognosis data to inform patient discussions.</p>
  </div>
  
  <div class="quick-hit">
    <h4>üìä Coronary Revascularization in the TAVR Era: Timing & Strategy</h4>
    <p><strong>Love A, et al. | Clin Med Insights Cardiol</strong> | <a href="https://pubmed.ncbi.nlm.nih.gov/41341906/" target="_blank">Full Text (Free PMC)</a><br><br>
    Review article synthesizing current evidence on PCI timing around TAVR. Good summary piece for Heart Team discussions and patient counseling.</p>
  </div>

  <div class="quick-hit">
    <h4>‚ö†Ô∏è Beta Blocker Withdrawal Post-MI: REBOOT Discussion</h4>
    <p><strong>EuroIntervention Letters</strong><br><br>
    Letter exchange on the REBOOT trial‚Äîbeta blocker withdrawal safety post-MI with preserved LVEF. Key point: ischemic safety confirmed, but symptom/QoL impact needs more study. Not strictly interventional, but relevant to post-PCI management.</p>
  </div>

  <div class="quick-hit">
    <h4>ü©∫ Transcatheter PVL Closure: Medium-Term Outcomes</h4>
    <p><strong>Albenque G, et al. | EuroIntervention</strong><br><br>
    Prospective multicenter registry (n=213) on transcatheter paravalvular leak closure. Medium-term outcomes and prognostic factors. Useful data if you're developing this service line.</p>
  </div>
</div>

<div class="download-section">
  <a href="pdf/2026-02-03-printable.html" class="download" target="_blank">üì• View Printable Brief</a>
</div>

<p class="footer">Compiled by Vienna | February 3, 2026<br>Sources: EuroIntervention, PubMed, Open Heart</p>
</div>
</body>
</html>
